George Abercrombie joins Ziopharm's board
This article was originally published in Scrip
Ziopharm Oncology (US) has appointed George Abercrombie to its board of directors. He will also serve as a member of the board’s compensation committee, as well as the nominating and corporate governance committee. The company has also elected Dr Murray Brennan chairman of the board. Mr Abercrombie most recently served as president and CEO of Roche North America and has more than 30 years' experience in the pharmaceutical industry. Before joining Roche in 2001, Mr Abercrombie was senior vice-president of commercial operations at Glaxo Wellcome.
You may also be interested in...
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.